Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CK Life Sciences Int'l., (Holdings) Inc.
長 江 生 命 科 技 集 團 有 限 公 司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 0775)

BUSINESS UPDATE ON PRECLINICAL STUDIES OF CANCER VACCINES

CK Life Sciences Int'l., (Holdings) Inc. (the "Company") announces that Sequencio Therapeutics Company Limited ("Sequencio"), a wholly owned subsidiary of the Company will present new data from its lead cancer vaccine programmes, TROP2 circRNA-LNP vaccine and PD-L1/PRAME dual-antigen vaccine, respectively, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2026 in Phoenix, Arizona, USA.

Together, the studies provide preclinical support for multiple elements of Sequencio's Prime-Infiltrate-Ignite-Translate (PINT) research framework. The findings demonstrate the induction of antigen-specific immune responses, enhanced immune activity within the tumour microenvironment and approaches to addressing immune suppression, while the use of humanised models helps assess the potential translational relevance of these observations.

The two programmes take complementary approaches to addressing two key challenges in cancer immunotherapy: generating effective immune recognition of cancer cells and overcoming mechanisms of tumour-mediated immune suppression. One combines tumour-targeted vaccination with checkpoint inhibition, while the other integrates tumour recognition and immune modulation within a single dual-antigen vaccine design.

The Company considers that the findings provide preclinical evidence supporting the intended mechanisms of action of Sequencio's cancer vaccines and demonstrate how these programmes may generate and sustain anti-tumour immune responses. In addition, the findings may also help inform future clinical development in perioperative settings, where lower tumour burden may give vaccine-induced immunity a greater opportunity to control residual disease. The Company believes these encouraging results provide further support for the continued advancement of both vaccine candidates toward human clinical trials.

It should be noted that the research is only at the preclinical stage and the Company has not yet commenced clinical trials for these vaccines and accordingly, there is no assurance of the outcome. Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 4 November 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).